WAYNE, Pa., May 15, 2017 /PRNewswire/ -- Egalet
Corporation (NASDAQ: EGLT), a fully integrated specialty
pharmaceutical company focused on developing, manufacturing and
commercializing innovative treatments for pain and other
conditions, announced today that researchers will present five
scientific posters at the 36th Annual American Pain
Society (APS) meeting May 17 to 20,
2017 in Pittsburgh.
The following posters will be presented during the APS poster
session on Thursday, May 18.
- Bioequivalence of abuse-deterrent, immediate-release (ADIR)
oxycodone compared with IR oxycodone without abuse-deterrent
properties. Authors: Sean Gill,
MA, John Lawler, BS,
Gwendolyn Niebler, DO, Jeffrey M. Dayno, MD
-
- Time: 9:30-11 a.m., poster #
239
- Novel design to evaluate the efficacy and safety of an
abuse-deterrent, extended-release oxycodone product candidate in
patients with moderate to severe chronic low back pain. Authors:
Richard L. Rauck, MD, John Markman, MD, Srinivas Nalamachu, MD,
Martin E. Hale, MD, Jeffrey M. Dayno, MD, Gwendolyn Niebler, DO, John Lawler, BS, Erin
Coyle, BSN, Janene
O'Brien-Giemza, BS, Nathaniel P.
Katz, MD
-
- Time: 9:30-11 a.m., poster #
237
- Natural History of Prescription Opioid Misuse/Abuse: A
Qualitative Investigation. Authors: Kimberlee J. Trudeau, Ph.D., Kelly A. Manser, B.A., Michael Behling, B.A., Colville Brown, M.D., Wendy Niebler, D.O., Simon H. Budman, Ph.D.
-
- Time: 3:45-5:15 p.m., poster #
228
- The relationship between the pharmacokinetics of morphine
abuse-deterrent, extended-release, injection-molded tablets and
pharmacodynamic outcomes in oral and intranasal human abuse
potential studies. Authors: Ben Vaughn, MS, Colville Brown, MD, Jack
Lawler, BS, Karsten
Lindhardt, MSc, PhD, DBE, Gwendolyn
Niebler, DO, Jeffrey M.
Dayno, MD
-
- Time: 3:45-5:15 p.m., poster #
238
- A harm reduction model to quantify potential misuse/abuse
reduction and misuse/abuse-related events avoided from
extended-release abuse deterrent opioids. Authors: Alan White, PhD; Tim Spittle BS; Wendy Niebler, DO; Colville Brown, MD; Jeff
Dayno, MD; Nathaniel Katz,
MD, MS
-
- Time: 3:45-5:15pm, poster #
236
About The American Pain Society
Based in Chicago, the American Pain Society (APS) is a
multidisciplinary community that brings together a diverse group of
scientists, clinicians and other professionals to increase the
knowledge of pain and transform public policy and clinical practice
to reduce pain-related suffering. APS is the professional
home for investigators involved in all aspects of pain research
including basic, translational, clinical and health services
research to obtain the support and inspiration they need to
flourish professionally. APS strongly advocates expansion of
high quality pain research to help advance science to achieve
effective and responsible pain relief. For more information
on APS, visit www.americanpainsociety.org.
About Egalet
Egalet, a fully integrated specialty pharmaceutical company, is
focused on developing, manufacturing and commercializing innovative
treatments for pain and other conditions. Egalet has three approved
products: ARYMO® ER (morphine sulfate) extended-release tablets for
oral use only –CII, developed using Egalet's proprietary Guardian™
Technology, OXAYDO® (oxycodone HCI, USP) tablets for oral use only
–CII and SPRIX® (ketorolac tromethamine) Nasal Spray. Using
Guardian Technology Egalet is developing a pipeline of
clinical-stage, product candidates including Egalet-002, an
abuse-deterrent, extended-release, oral oxycodone formulation for
the management of pain severe enough to require daily,
around-the-clock, long-term opioid treatment and for which
alternative treatment options are inadequate. Guardian Technology
can be applied broadly across different classes of pharmaceutical
products and can be used to develop combination products that
include multiple active pharmaceutical ingredients with similar or
different release profiles. For full prescribing information on
ARYMO ER, including the boxed warning and medication guide, please
visit arymoer.com. For full prescribing information on SPRIX,
including the boxed warning and medication guide, please visit
sprix.com. For full prescribing information on OXAYDO, including
the boxed warning and medication guide, please visit oxaydo.com.
For additional information on Egalet, please visit egalet.com.
Investor and Media Contact:
E. Blair Clark-Schoeb
Senior Vice President, Communications
Email: bcs@egalet.com
Tel: 917-432-9275
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/egalet-announces-scientific-presentations-at-american-pain-society-meeting-300457169.html
SOURCE Egalet Corporation